SCM
Silverarc Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.87M | Buy |
+82,023
| New | +$3.87M | 0.71% | 30 |
|
|
2024
Q1 | – | Sell |
-50,000
| Closed | -$3.02M | – | 84 |
|
|
2023
Q4 | $3.02M | Buy |
+50,000
| New | +$3.02M | 0.9% | 40 |
|
|
2023
Q3 | – | Sell |
-200,000
| Closed | -$10.2M | – | 81 |
|
|
2023
Q2 | $10.2M | Buy |
200,000
+94,250
| +89% | +$4.81M | 3.16% | 9 |
|
|
2023
Q1 | $2.26M | Buy |
+105,750
| New | +$2.26M | 0.93% | 38 |
|
|
2022
Q1 | – | Sell |
-131,823
| Closed | -$1.3M | – | 73 |
|
|
2021
Q4 | $1.3M | Sell |
131,823
-92,083
| -41% | -$911K | 0.53% | 49 |
|
|
2021
Q3 | $2.22M | Sell |
223,906
-10,114
| -4% | -$100K | 1.26% | 25 |
|
|
2021
Q2 | $2.42K | Buy |
234,020
+5,535
| +2% | +$57 | 1.08% | 32 |
|
|
2021
Q1 | $2.33M | Buy |
228,485
+13,414
| +6% | +$137K | 1.27% | 29 |
|
|
2020
Q4 | $2.45M | Buy |
+215,071
| New | +$2.45M | 1.42% | 24 |
|